- Open Access
Generation of myogenic progenitor cell-derived smooth muscle cells for sphincter regeneration
Stem Cell Research & Therapy volume 11, Article number: 233 (2020)
Degeneration of smooth muscles in sphincters can cause debilitating diseases such as fecal incontinence. Skeletal muscle-derived cells have been effectively used in clinics for the regeneration of the skeletal muscle sphincters, such as the external anal or urinary sphincter. However, little is known about the in vitro smooth muscle differentiation potential and in vivo regenerative potential of skeletal muscle-derived cells.
Myogenic progenitor cells (MPC) were isolated from the skeletal muscle and analyzed by flow cytometry and in vitro differentiation assays. The differentiation of MPC to smooth muscle cells (MPC-SMC) was evaluated by immunofluorescence, flow cytometry, patch-clamp, collagen contraction, and microarray gene expression analysis. In vivo engraftment of MPC-SMC was monitored by transplanting reporter protein-expressing cells into the pyloric sphincter of immunodeficient mice.
MPC derived from human skeletal muscle expressed mesenchymal surface markers and exhibit skeletal myogenic differentiation potential in vitro. In contrast, they lack hematopoietic surface marker, as well as adipogenic, osteogenic, and chondrogenic differentiation potential in vitro. Cultivation of MPC in smooth muscle differentiation medium significantly increases the fraction of alpha smooth muscle actin (aSMA) and smoothelin-positive cells, while leaving the number of desmin-positive cells unchanged. Smooth muscle-differentiated MPC (MPC-SMC) exhibit increased expression of smooth muscle-related genes, significantly enhanced numbers of CD146- and CD49a-positive cells, and in vitro contractility and express functional Cav and Kv channels. MPC to MPC-SMC differentiation was also accompanied by a reduction in their skeletal muscle differentiation potential. Upon removal of the smooth muscle differentiation medium, a major fraction of MPC-SMC remained positive for aSMA, suggesting the definitive acquisition of their phenotype. Transplantation of murine MPC-SMC into the mouse pyloric sphincter revealed engraftment of MPC-SMC based on aSMA protein expression within the host smooth muscle tissue.
Our work confirms the ability of MPC to give rise to smooth muscle cells (MPC-SMC) with a well-defined and stable phenotype. Moreover, the engraftment of in vitro-differentiated murine MPC-SMC into the pyloric sphincter in vivo underscores the potential of this cell population as a novel cell therapeutic treatment for smooth muscle regeneration of sphincters.
Sphincters are circular muscles controlling the movement of solids and/or liquids. They consist of either skeletal muscles, such as the external anal sphincter or smooth muscles, such as the internal anal and pyloric sphincters [1, 2]. Malfunction of the sphincter muscles of the anus and the pylorus is associated with fecal incontinence and gastroparesis, respectively [3, 4]. Although not life-threatening, fecal incontinence severely affects patients’ quality of life . The prevalence rate of fecal incontinence is estimated to be up to 12% in men and women [6, 7], and the main type, with approximately 78% of all cases , results from the degeneration of the smooth muscle of the internal anal sphincter which causes passive fecal incontinence . Conservative treatments such as the application of bulking agents have limited success in patients with high incontinence severity, and surgical approaches have high morbidity and complication rates . Thus, there is a strong need for cell therapeutic approaches for the regeneration of smooth muscle tissue building sphincters.
The functionality of smooth muscle relies on highly differentiated smooth muscle cells expressing contractile proteins, such as alpha smooth muscle actin (aSMA), desmin, and smoothelin (SMTN) [11,12,13], as well as functional voltage-gated calcium and potassium channels, enabling regulated cell contraction .
Treatment of multipotent mesenchymal stromal cells (MSC) with transforming growth factor beta (TGFb) has been shown to induce the expression of smooth muscle-specific genes under the regulation of the CArG box via the signaling through SMADs, serum response factor, and myocardin [15,16,17]. Thus, using MSC of various origins, the application of TGFb1 during differentiation was shown to upregulate the expression of smooth muscle-specific contractile proteins  and functional calcium and potassium channels .
Skeletal muscle tissue is a source of stem and progenitor cells expected to be endowed with high regenerative potential, such as MSC and satellite cell-derived myogenic progenitor cells (MPC) . Skeletal muscle-derived CD56+ cells have been shown to improve patients’ external anal sphincter-associated fecal incontinence in clinics [21,22,23,24,25,26]. Furthermore, skeletal muscle-derived cells were found to engraft into the bladder detrusor muscle improving bladder function . However, limited knowledge exists regarding the differentiation potential and regenerative capacity of skeletal muscle-derived cells for the treatment of smooth muscle-related deficiencies , particularly for sphincter smooth muscle regeneration.
In the study presented here, we generated in vitro smooth muscle cells from skeletal muscle-derived myogenic progenitor cells and evaluated their cell therapeutic potential for sphincter regeneration.
Isolation and culture of human skeletal muscle-derived cells
Muscle samples of human origin were retrieved as a part of a clinical trial (EudraCT Number: 2010-021463-32), and residual material of patients agreeing to further usage of their cells was used for research purposes following informed consent. Cells were isolated from muscle biopsies (Musculus pectoralis major or Latissimus dorsi) and expanded under cGMP environment as described before [29, 30]. Cells were maintained by standard cell culture methods. Briefly, cells were cultured in a growth medium containing Ham’s F-10 basal medium supplemented with 10% FCS (inactivated at 57 °C, 40 min, Life Technologies, UK), bFGF (CellGenix, Freiburg, Germany), and gentamicin (Sandoz GmbH, Austria) and incubated at 37 °C, 5% CO2. Counting of cells was performed on Nucleocounter™ (ChemoMetec, Allerod, Denmark) according to the manufacturer’s instructions.
Isolation, culture, and transplantation of murine skeletal muscle-derived cells
Murine skeletal muscle-derived cells were obtained from skeletal muscle biopsies of Gt (ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J, in short, TdTomato mice (Jackson Laboratory, ME, USA). Adult mice were sacrificed by cervical dislocation. Next, samples were obtained from the longissimus dorsi, gastrocnemius, and tibialis anterior muscles using scissors and scalpel. The muscles were transferred into a sterile petri dish and covered with 1× PBS. Then, using tweezers and a scalpel, the remaining connective tissue was removed from the skeletal muscle and discarded. Afterwards, the muscle tissue was digested using the skeletal muscle dissociation kit (MiltenyiBiotec GmbH, Bergisch Gladbach, Germany) following the manufacturer’s instructions. In order to separate myogenic progenitor cells (mMPC) from non-myogenic cells, a satellite cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany) was used according to the manufacturer’s instructions. Collected mMPC and non-myogenic cells were centrifuged for 10 min at 400×g and resuspended in mouse growth medium, consisting of DMEM/Ham’s F12 supplemented with 20% FCS and bFGF. Murine cells were cultivated on collagen-coated culture flasks, prepared by covering the surface of the culture flasks with collagen I from the rat tail (Sigma-Aldrich Co. LLC, MO, USA) diluted 1:10 1× PBS for 1 h at 37 °C. Subcultivation, cryopreservation, cell count, and immunostainings were performed like for human skeletal muscle-derived cells.
Separation of MPC and MSC by MACS
MSC (CD56− skeletal muscle-derived cells) were separated from MPC (CD56+ skeletal muscle-derived cells) by magnetic-activated cell sorting (MACS). The human CD56 MicroBeads kit (MiltenyiBiotec GmbH, Bergisch Gladbach, Germany) was used for the separation of CD56+ and CD56− cells according to the manufacturer’s instructions.
Human bladder smooth muscle cells
Primary human bladder smooth muscle cells (HBdSMC-c) were obtained from PromoCell® (Cat. No.: C-12571) and cultivated in growth medium (Ham’s F10, 10% FCS, bFGF, gentamicin) for expansion to reach synthetic smooth muscle cells (s-hBd-SMC). Phenotype switch to contractile smooth muscle cells (hBd-SMC) was induced by switching to smooth muscle differentiation medium and cultivating cells therein for 6 days.
Flow cytometry analysis was performed on a Guava easyCyte 6HT 2 L flow cytometer (Merck Millipore, Darmstadt, Germany) as described before . Before measurement, 40,000 cells were resuspended in 195 μl 1× PBS and incubated after addition of 5 μl CD34-PE, CD56-PE, CD146-PE, IgG1-PE, IgG1-FITC, CD90-PE, CD105-PE, HLA-DR-PE, CD45-PE (all from Beckman Coulter, CA, USA), CD49a-FITC (MiltenyiBiotec GmbH, Bergisch Gladbach, Germany), CD14-PE (Thermo Scientific, MA, USA), CD19-PE (BioLegend, CA, USA), or CD73-PE (Becton Dickinson, NJ, USA) for 30 min at 4 °C in the dark following a washing step with 1× PBS. Histograms and dot plots were generated with a minimum of 5000 events at a sample flow rate of 1.8 μl/ml. Positive staining was obtained by comparison with isotype control set as 99% negative or comparison to control (negative) cells.
Immunofluorescence staining on cell cultures
Immunofluorescence staining was performed directly on gelatine-coated 24-well plates or glass coverslips placed in 6-well plates as described before . For fluorescent immunolabeling of alpha smooth muscle actin (aSMA), smoothelin, smooth muscle myosin heavy chain (SM-MHC), or desmin, cells were incubated with a mouse anti-actin alpha smooth muscle (Sigma-Aldrich Co. LLC, MO, USA), mouse anti-smoothelin (Merck Millipore, MA, USA), anti-smooth muscle myosin heavy chain (Merck Millipore, MA, USA), or rabbit anti-desmin (Thermo Scientific, MA, USA) antibody, respectively, each diluted 1:100 in blocking medium. Secondary goat anti-mouse Alexa488 or donkey anti-rabbit Alexa547-conjugated antibodies (Thermo Scientific, MA, USA), diluted 1:200 in blocking medium, were used. Counterstaining of the nuclei was performed by incubating the cells with Hoechst33342 (Sigma-Aldrich Co. LLC, MO, USA) diluted to a final concentration of 2 μg/ml in PBST (0.1% Triton X-100). Cells were mounted with Entellan® (Merck Millipore, MA, USA) and sealed with glass coverslips. Stainings were compared to procedures without primary antibodies and cells negative for tested antibodies. Double staining procedures were performed by simultaneous incubation with mouse anti-aSMA or mouse anti-smoothelin and rabbit anti-desmin primary antibodies. This was followed by incubation with combinations of secondary antibodies: goat anti-mouse Alexa488 and goat anti-rabbit Alexa547. Double stain procedures were controlled for unspecific binding of secondary antibodies by omitting one first antibody demonstrating the absence of cross staining with the respective other secondary antibodies.
Skeletal muscle differentiation
Skeletal muscle-derived cells were differentiated in 24-well Nunclon™ Delta Surface plastic plates (Thermo Scientific, MA, USA) by replacing the growth medium with Skeletal Muscle Cell Differentiation Medium (500 ml, PromoCell GmbH, Germany), supplemented with 10 ml of Skeletal Muscle Cell Differentiation Medium Supplement Pack (PromoCell GmbH, Germany) and 240 μl gentamicin (8 mg/ml, Sandoz GmbH, Austria) as described before .
Adipogenic, chondrogenic, and osteogenic differentiation
For adipogenic, chondrogenic, and osteogenic differentiation in vitro, each 500,000 cells were seeded onto 6-well plates (NUNC, Thermo Scientific, MA, USA) and cultivated in a growth medium for 24 h at 37 °C, 5% CO2. Next, cells were washed once with 5 ml DMEM/Ham’s F12 and covered with each 5 ml adipogenic, chondrogenic, or osteogenic differentiation medium. Adipogenic, chondrogenic, and osteogenic differentiation medium consisted of StemXVivo™ Osteogenic/Adipogenic Base Medium (R&D Systems Inc., MN, USA), supplemented with StemXVivo Human/Mouse/Rat Adipogenic (R&D Systems Inc., MN, USA), StemXVivo Human Osteogenic Supplement (R&D Systems Inc., MN, USA), or STEMPro® Chondrogenesis Supplement (Gibco®, Thermo Scientific, MA, USA), respectively, according to the manufacturer’s instructions. Differentiation media were further supplemented with gentamicin (Sandoz GmbH, Austria) to reach a final concentration of 3.83 μg/ml. Cells were cultivated each for 14 days in respective differentiation media, which were changed every 2–3 days. After 14 days of cultivation, successful differentiation was assessed by the presence of adipocytes, chondrocytes, and osteocytes visualized by oil red o, alcian blue, and alizarin red s staining, respectively. Quantification of oil red o, alcian blue, and alizarin red s staining was performed on microscopic images of multiple individual experiments by ImageJ software package. Therefore, images were loaded and color channels split. Red channels were used for oil red o and alizarin red s stainings, while blue channel was used for alcian blue stainings. The background was eliminated by setting a common threshold, and the average pixel intensity per field was acquired for quantification by ImageJ.
Smooth muscle differentiation
To induce smooth muscle differentiation of MPC, murine MPC and MSC to MPC-SMC, and murine MPC-SMC and MSC-SMC, cells cultivated with growth medium to a confluency of about 70% were washed once with DMEM/F12 (Thermo Scientific, MA, USA). Next, cells were covered with smooth muscle differentiation medium, consisting of DMEM/F12 supplemented with recombinant human TGFb1 (Thermo Scientific, MA, USA), heparin sodium salt from the porcine intestinal mucosa (Sigma-Aldrich Co. LLC, MO, USA), fetal calf serum (Gibco, Thermo Scientific, MA, USA), and gentamicin (Sandoz GmbH, Tirol, Austria) to a final concentration of 10 ng/ml, 5% (v/v), and 3.84 μg/ml, respectively. Finally, cells were cultivated in smooth muscle differentiation medium for 3–6 days at 37 °C, 5% CO2. The medium was changed every 3–4 days.
Fusion index calculation
Fusion index (FI) calculation was performed as described before . Fusion index was calculated for each captured field of view by dividing the number of nuclei within the tubes with the total number of nuclei per field, followed by the calculation of the mean for all analyzed fields. Only cells that have at least 3 nuclei were considered as myotubes. For statistical analysis, at least 3 populations derived from different patients were analyzed for each group.
Acetylcholinesterase activity measurement
Acetylcholinesterase (AChE) activity measurement was performed as described before . In short, the medium was carefully removed from cells grown on a 24-well plate with the immediate addition of 300 μl 0.5 mM DTNB solution (prepared in phosphate buffer, pH 7.2 with 0.1% Triton X-100). After 2 min of incubation at room temperature in the dark, 50 μl of 5.76 mM ATI (prepared in distilled water) was added. The reaction contents were incubated for 60 min at 30 °C in the dark followed by the OD measurement at 412 mM on an Anthos Zenyth 340rt microplate reader (Biochrom Ltd., Cambridge, UK). AChE activity (mUrel) was normalized per gram protein of lysed cells.
Creatine kinase activity measurement
The medium from adherent cells grown on a 24-well plate was gently removed, and cells were washed with 1 ml of Tyrode’s salt solution (Sigma-Aldrich Co. LLC, MO, USA). Immediately afterwards, 70 μl lysis buffer was added directly onto the cells. Lysis buffer was prepared by adding 10 μl of Triton X-100 to 10 ml of dH2O (LC-MS-Ultrachromasol, Fluka). After 5 min incubation at 4 °C in the dark, 400 μl of CK-NAC (Thermo Scientific, MA, USA), previously dissolved by adding 10 ml dH2O, was added. The reaction was analyzed in an Anthos Zenith 340rt microplate reader (Biochrom Ltd., Cambridge, UK) set to 30 °C, by OD absorbance measurement at 340 nm. If not otherwise mentioned, OD340 nm values taken 21 min after the addition of CK-NAC were used for subsequent analysis. CK activity in mUrel was calculated according to the manufacturer’s instructions and if not otherwise mentioned normalized per gram protein of lysed cells.
Protein content of cell lysates for AChE and CK activity measurement was determined using the Pierce BCA Protein Assay Kit (Thermo Scientific, MA, USA) according to the manufacturer’s instructions by measuring the OD at 540 nm with an Anthos Zenyth 340rt microplate reader (Biochrom Ltd., Cambridge, UK).
Standard light/fluorescence microscopy
Phase-contrast and fluorescence microscopy at × 200–600 magnification was carried out on cells cultivated on plastic cell culture vessels or glass coverslips using a Nikon Eclipse TE 2000-U microscope (Nikon Corporation, Tokyo, Japan). Representative fields were photographed with Digital Sight DS-L1 system (Nikon Corporation, Tokyo, Japan).
For both, injection of murine MPC-SMC into the pyloric sphincter as well as injection of murine MPC into the tibialis anterior muscle, adult female SHO-PrkdcscidHrhr mice were anesthetized by applying ketamine, xylazin, and acepromazin intraperitoneally. Cryopreserved murine MPC-SMC were freshly thawed, washed once with 1× PBS, and resuspended in 1× PBS to reach a final concentration of 40,000 000 cells/ml. Twenty-five microliters of the cell suspension (containing 1,000,000 cells) was then mixed with 5 μl FluoSpheres® polystyrene, 15-μm yellow-green beads (Life Technologies, Thermo Scientific, MA, USA). For MPC-SMC injection into the pyloric sphincter, a median laparotomy was performed followed by localization of the pyloric sphincter region and application of 30 μl cell-fluosphere mixture using a 30-G needle attached to a 1-ml syringe. The peritoneum muscle and skin layers were closed separately by running sutures with 6-0 Ethicon PDS plus absorbable monofilaments (Johnson & Jonson, NJ, USA). For MPC injection into the tibialis anterior muscle, anesthetized mice were injected with 30 μl cell-fluosphere mixture using a 28-G needle attached to a 1-ml syringe through the skin into the skeletal muscle.
Pyloric sphincter imaging
Imaging of fresh isolated pyloric sphincter regions 12 weeks after MPC-SMC injection was performed with an IVIS Spectrum (PerkinElmer, MA, USA) using the Living Image® software version 4.5.2 (PerkinElmer, MA, USA) according to the manufacturer’s instructions. In short, pyloric sphincters of injected and control SHO mice were placed on a glass petri dish and placed within the IVIS system. Fluorescence pictures at a height of 2 cm with automated exposure times for the corresponding absorption and emission wavelengths of TdTomato and yellow Fluosphere beads were taken. Post hoc, signal intensities were adjusted in order to get rid of background signals by comparing with sphincter explants from control mice.
For histological analysis, animals were deeply anesthetized with isoflurane and sacrificed by cervical dislocation. The tissue of interest was immediately dissected and cryo-fixed by plunging into liquid nitrogen-cooled 2-methylbutane. Tissue was cut at 15 μm on a Leica 1950 Cryostat, and slices were collected on SuperFrost plus slides and kept at − 20 °C until further processing. For immunohistological analysis, sections were fixed with 4% PFA and washed with PBS containing 0.1% Tween-20 (Sigma-Aldrich). Blocking and antibody dilution were performed using a PBS solution containing 1% bovine serum albumin fraction (Sigma-Aldrich), 0.2% fish skin gelatine (Sigma-Aldrich), and 0.1% Tween-20 (Sigma-Aldrich). Primary antibodies against tdTomato (Sicgen) or aSMA (Thermo Scientific, MA, USA) were diluted 1:100 in blocking media, and incubation was performed overnight at 4 °C. Secondary antibodies (Thermo scientific) were diluted 1:500 and applied at room temperature for 4 h. The nuclei were stained with DAPI diluted to 0.5 μg/ml working concentration (Sigma-Aldrich). Slices were subsequently mounted using Prolong Gold Antifade (Life Technologies). Fluorescence images were acquired using a LSM 710 confocal microscope and ZEN 2011 Black Software (Carl Zeiss).
Patch-clamp analysis was performed according to a previously published protocol , with slight experiment-specific adaptions. Procedures were conducted as follows. Electrophysiological recording was performed in a whole-cell configuration using an Axopatch 200A patch clamp amplifier (Axon Instruments, Foster City). Patch pipettes with resistances of 1 to 4 MΩ were made from borosilicate glass (GC150F-7.5, Clark Electromedical Instruments, UK) and filled with pipette solution. All data were digitized using a DIGIDATA 1200 interface (Axon Instruments, Foster City), smoothed by means of a four-pole Bessel filter, and saved to disc. Current traces were sampled at 10 kHz and filtered at 2 kHz. The pClamp software package (version 10.0 Axon Instruments, Inc.) was used for data acquisition. Microcal Origin 7.0 was used for analysis. If not otherwise mentioned, reagents were obtained from Sigma-Aldrich. Inward current of voltage-dependent Cav channels was evoked by applying 500-ms depolarizing pulses from a holding potential of − 50 to 50 mV. Superimposed current traces of Kv channels were evoked by step depolarizing pulses between − 80 and 60 mV in steps of 20 mV from a holding potential of − 80 mV in MPC, MPC-SMC, and hBd-SMC.
Total RNA of 1 × 106 MPC or MSC, each cultured either in growth medium or 6 days in differentiation medium, was isolated by the RNEasy Kit (QIAGEN, Hilden, Germany) according to the manufacturers’ instructions. Sample preparation for microarray hybridization was carried out as described in the NuGEN Ovation PicoSL WTA System V2 and NUGEN Encore Biotin Module manuals (NuGEN Technologies, Inc., San Carlos, CA, USA). Hybridized arrays were washed and stained in an Affymetrix Fluidics Station FS450, and the fluorescent signals were measured with an Affymetrix GeneChip Scanner 3000 7G. The Affymetrix GeneChip Command Console v4.1.3 software controlled fluidics and scan functions. The Affymetrix Service Provider and Core Facility, “KFB - Center of Excellence for Fluorescent Bioanalytics” (Regensburg, Germany) performed the sample processing.
Microarray data analysis
Summarized probe set signals in log2 scale were calculated by using the RMA algorithm with the Affymetrix GeneChip Expression Console v1.4 Probeset IDs with the highest log2 fold change between MPC and MPC-SMC were used for subsequent analysis and comparison to log2 fold changes between MSC and MSC-SMC. Heat maps were generated with the Multiple Expression Viewer (MeV 3.1.0) software in order to visualize log2 fold changes and perform hierarchical clustering as well as k-means clustering according to Euclidean distance. Genes with Log2 FC of 1 or more were considered upregulated and genes with a log2 FC of − 1 or less as downregulation.
Quantitative data analysis
Data analysis for descriptive and inferential statistics was performed by using the GraphPad Prism software version 5.0. If not otherwise mentioned, data is presented as mean ± SD. For inferential statistics, p values below 0.05 were considered as statistically significant differences. p values below 0.05, 0.01, and 0.001 are visualized as *, ** and ***, respectively.
MPC isolation and characterization
Human skeletal muscle-derived cells were isolated from adult human skeletal muscle tissue. Both CD56+ and CD56− cells were enriched by MACS as described before . CD56+ cells, known to be committed to the myogenic lineage , are referred to as myogenic progenitor cells (MPC) hereafter, while CD56− cells, hypothesized to be utmost multipotent mesenchymal stromal cells, are termed MSC. We characterized MPC and MSC following isolation to confirm the efficiency of their separations (Fig. 1a). They were tested for the presence of mesenchymal lineage markers (CD105, CD90, CD73) and hematopoietic markers (CD14, CD19, CD45, CD34, MHCII), constituting the consensus minimal panel for the characterization of MSC by flow cytometry . CD56+ MPC highly expressed all mesenchymal lineage markers tested and were negative for tested hematopoietic markers. Thus, our marker panel confirmed the mesenchymal character of CD56+ MPC (Fig. 1a).
Next, MPC and MSC were tested in vitro for their differentiation potential into the adipogenic, chondrogenic, osteogenic, and skeletal myogenic lineages using the appropriate culture conditions. The absence of oil red o- and alizarin red s-positive cells revealed the incapacity of MPC to differentiate into adipocytes and osteocytes, respectively (Fig. 1b, c). Furthermore, only low levels of chondrogenic differentiation occurred according to the scarce cells with alcian blue staining detected (Fig. 1b, c). In contrast, differentiation of the CD56− MSC led to numerous cells positive for oil red o, alcian blue, and alizarin red s following cultivation in adipogenic, chondrogenic, and osteogenic differentiation medium, respectively (Fig. 1b, c). Quantification of staining intensities of MSC compared to MPC following differentiation in vitro revealed a significantly higher intensity in oil red o (p = 0.0117), alcian blue (p = 0.0020), and alizarin red s (p = 0.0012) staining. These observations confirmed the multipotent mesenchymal stromal character of CD56− MSC as defined by the International Society for Cellular Therapy . However, desmin-positive multinucleated myotubes were detected in MPC but not MSC cultures (Fig. 1b), and a significantly higher fusion index (p = 0.0007) was found within MPC compared to MSC (Fig. 1c). Hence, these results confirmed that MPC were cells of mesenchymal origin and committed to the myogenic lineage. In contrast, muscle-derived CD56− MSC were capable of adipogenic, chondrogenic, and osteogenic differentiation but were not able to undergo myogenic differentiation in vitro.
In vitro differentiation of MPC to myogenic progenitor cell-derived smooth muscle cells
In order to assess the smooth muscle differentiation potential of MPC, that were cultivated in a smooth muscle differentiation medium, which has been previously employed on multipotent mesenchymal stromal cells derived from induced pluripotent stem cells . MPC-derived smooth muscle cells (MPC-SMC) were analyzed for the expression of intracellular contractile smooth muscle proteins (aSMA, smoothelin) [13, 33] as well as the general myogenic marker desmin  by fluorescent immunostaining. Whereas aSMA and smoothelin were hardly detectable in MPC, MPC-SMC showed detectable amounts of both proteins (Fig. 2a). The proportion of aSMA- and smoothelin-positive cells was significantly higher in MPC-SMC (84.77 ± 13.02% aSMA- and 86.70 ± 12.45% smoothelin-positive cells) compared to MPC (1.37 ± 2.11% aSMA- and 0.78 ± 0.85% smoothelin-positive cells) at a p value of p < 0.001 (aSMA) and p < 0.001 (smoothelin) (Fig. 2b). In contrast, no significant difference was observed in a number of desmin+ cells between MPC (62.68 ± 4.33%) and MPC-SMC (65.93 ± 8.58%) at a p value of p = 0.5897, suggesting smooth muscle lineage commitment of MPC-SMC without losing general myogenic fate. In addition, the proliferation of MPC was addressed following 6 days of culture in growth or smooth muscle differentiation medium. The increase in the number of cells in smooth muscle differentiation medium (MPC-SMC) was significantly lower (p = 0.0179) during the 6-day cultivation period compared to MPC in growth medium (Fig. 2c), which is consistent with the observed switch to differentiation towards a post-mitotic phenotype. Finally, the expression of CD146 and CD49a, associated with the vascular smooth muscle commitment of MSC  and expressed during smooth muscle development , greatly increased in MPC when differentiated to MPC-SMC by cultivation for 6 days in smooth muscle differentiation medium. Percentage of both CD146 and CD49a surface marker-positive cells were significantly higher at a p value of p = 0.0033 (CD146) and p = 0.0031 (CD49a) in MPC-SMC (76.53 ± 9.56% CD146- and 39.49 ± 7.40% CD49a-positive cells) than in MPC (32.78 ± 15.46% CD146- and 7.59 ± 5.51% CD49a-positive cells) (Fig. 2d, e and S1 Fig.).
A microarray analysis of differentiating MPC was carried out to monitor the changes in gene expression associated with SMC differentiation [35, 37, 38], myogenic commitment , and smooth muscle contraction . Changes in the gene expression occurring when MPC were differentiated to MPC-SMC were compared to those when MSC were differentiated to MSC-SMC, both by cultivation in smooth muscle differentiation medium. We observed that 25 genes (20.33%) of the 123 tested genes were up- and 4 genes (3.25%) downregulated during MPC to MPC-SMC differentiation. Among the genes upregulated in MPC-SMC, we confirmed our observation of an increase in CD49a (ITGA1) and smoothelin (SMTN) expression. Further, genes upregulated belong to the KEGG cluster and other known smooth muscle marker genes: PPP1R14A, KCNMB1, PLCB4, ACTG2, ITPR1, ADCY6, CALCRL, KCNMA1, GNA13, CNN1, ADCY2, KCNMB4, GUCY1A3, ARAF, PPP1R12A, MAPK1, CALD1, KCNMB2, PRKACB, ARHGEF11, PPP1R12C, ITPR2, and PLCB1 (Fig. 3a). Although CD146 (MCAM) surface protein expression was found to be upregulated in MPC-SMC, MCAM gene expression was not upregulated in the microarray experiments, suggesting a post-transcriptional regulation. Further, analysis of log2 FC changed gene expressions in MPC and MSC during differentiation to MPC-SMC and MSC-SMC led to the identification of up- and downregulated genes that were shared with differentiating MPC and MSC (Fig. 3b, c). Whereas PP1R14A, ACTG2, PLCB4, ITPR1, MAPK1, CNN1, ITGA1, and KCNMA1 were upregulated in MPC and MSC, PLA2G2A was downregulated in both cell types. Overall, 75.61% of genes analyzed were regulated similarly (i.e., up-, down-, stably regulated) in MPC and MSC upon differentiation using smooth muscle differentiation medium. More upregulated genes and less downregulated genes were found in differentiating MPC (20.33% up- and 3.25% downregulated) than differentiating MSC (12.20% up- and 5.69% downregulated). However, no significant difference in percent up- or downregulated genes was found between MPC and MSC. Taken together, these results suggest a differentiation efficiency of MPC to MPC-SMC being at least as good as MSC to MSC-SMC differentiation efficiency.
The smooth muscle phenotype of MPC-SMC and MSC-SMC was further compared to human bladder smooth muscle cells (hBd-SMC), following cultivation in smooth muscle differentiation medium for 6 days, by immunostaining. Immunodetection was performed against the smooth muscle marker proteins aSMA and smooth muscle myosin heavy chain (SM-MHC), as well as for desmin, a general myogenic marker, and vimentin, a contraction associated protein . MPC-SMC, MSC-SMC, and hBd-SMC expressed aSMA, SM-MHC, and vimentin. Additionally, MPC-SMC and hBd-SMC expressed desmin, which was not found in MSC-SMC (S2 Fig.). This observation substantiates that MPC-SMC differentiate to a smooth muscle phenotype resembling the one of hBd-SMC.
Stability of the MPC-SMC phenotype
To assess whether the phenotype of MPC-SMC is irreversible, aSMA protein expression was evaluated in MPC maintained in the growth medium, MPC cultivated in smooth muscle differentiation medium for 6 days (MPC-SMC) and in MPC-SMC that were cultured 3 additional days back in growth medium (De-diff MPC-SMC). As shown in Fig. 4a, MPC-SMC and De-diff MPC-SMC prominently expressed aSMA, in contrast to MPC. Significantly fewer aSMA-positive cells were found however in De-diff MPC-SMC (61.87 ± 11.84) compared to MPC-SMC (81.92% ± 16.50, p = 0.0196), thus demonstrating either a partial reversion of the smooth muscle phenotype or proliferation of MPC that did not differentiate to MPC-SMC in the first place and remained aSMA negative (Fig. 4d). Nevertheless, a substantial amount (> 60%) of the cells maintain their smooth muscle lineage commitment.
In order to address the skeletal muscle differentiation potential of MPC-SMC, as compared to MPC and De-diff MPC-SMC, their fusion competence based on the formation of multinucleated myotubes was assessed. Following the cultivation of all three cell types in skeletal muscle differentiation medium for 6 days, calculation of fusion index (FI) and quantification of the number of nuclei per tube were performed. Our results showed that MPC formed numerous multinucleated myotubes, whereas MPC-SMC and De-diff MPC-SMC formed only few myotubes (Fig. 4b, red arrows). Quantification of the FI demonstrated that significantly more MPC underwent skeletal myogenesis compared to MPC-SMC, revealing a decrease in the skeletal myogenic potential of MPC upon differentiation to MPC-SMC (Fig. 4c). Further, tubes formed by MPC-SMC contained significantly fewer nuclei than tubes formed by MPC (Fig. 4c). Additionally, no significant difference in terms of FI was detected between MPC-SMC and De-diff MPC-SMC (Fig. 4c). Moreover, acetylcholinesterase (AChE) and creatine kinase (CK), two enzymes upregulated during skeletal myogenesis [41, 42], were analyzed. Low AChE and CK activities were detectable in MPC and MPC-SMC. Upon induction of skeletal muscle differentiation, however, a significantly lower AChE and CK activity were found in MPC-SMC compared to MPC, suggesting a lower skeletal muscle differentiation potential of MPC-SMC (Fig. 4e).
Functional analysis of MPC-derived SMC in vitro
Since MPC were showing profound changes in gene and protein expression upon smooth muscle differentiation, we hypothesized that smooth muscle differentiation of MPC in vitro will also lead to functional maturation. It has been shown that TGFb1-induced differentiation of adipose tissue-derived multipotent mesenchymal stromal cells leads to the expression of functional voltage-sensitive calcium and potassium channels . Therefore, the presence of functional voltage-sensitive Cav and Kv channels was explored by patch-clamp analysis on MPC maintained in growth medium or differentiated to MPC-SMC by cultivation in smooth muscle differentiation medium for 6 days. As a control, hBd-SMC cultivated in smooth muscle differentiation medium for 6 days were analyzed in terms of their functional voltage-sensitive channels by patch-clamp analysis as well. MPC lacked both inward and outward currents from voltage-dependent calcium and voltage-dependent potassium channels. In contrast, MPC-SMC and hBd-SMC showed voltage-sensitive inward and outward currents for both cations (Fig. 5a, b).
Park et al. showed  that together with the expression of functional ion channels, in vitro contractility increased during smooth muscle differentiation of adipose-derived MSC. Therefore, both MPC and MPC-SMC were tested for contractility in a collagen gel lattice contraction assays. We also included in this analysis MSC, MSC-SMC, and hBd-SMCs. When MPC were differentiated to MPC-SMC, contractility increased from 22.11 ± 12.77% (MPC) to 46.57 ± 6.75% (MPC-SMC) (p = 0.0118). MSC-SMC were found to contract similarly (53.54 ± 22.53% gel contraction) compared to MPC-SMC (adjusted p = 0.5534). hBd-SMC were found to exhibit the highest contractility (85.84 ± 2.57%) and significantly more than MPC-SMC (p value adjusted for multiple testing, p = 0.0006) (S3 Fig.).
These results together suggest that upon smooth muscle differentiation, MPC functionally maturate to MPC-SMC in vitro.
Engraftment of MPC-derived SMC into smooth muscle tissue in vivo
We next addressed whether MPC-SMC are able to engraft into smooth muscle tissue in vivo. To this end, we isolated murine myogenic progenitor cells (mMPC) from transgenic TdTomato reporter mice and differentiated those mMPC to mMPC-SMC in vitro as described above. mMPC were found to be desmin+ and capable of fusing to multinucleated myotubes exhibiting AChE and CK activity following skeletal muscle differentiation (S4 Fig. A-D). In addition, mMPC were able to fuse to and/or with host myofibers following implantation into the skeletal muscle tissue of immunodeficient mice (S4 Fig. E, F). Following smooth muscle differentiation of mMPC, resulting mMPC-SMC were highly positive for desmin (77.60 ± 2.69%) and aSMA (80.00 ± 14.48%) (Fig. 6a), similar to human MPC-SMC, described above. mMPC-SMC, together with fluorescent beads, were transplanted into the pyloric sphincter of immunodeficient SHO mice. mMPC-SMC expressing the reporter TdTomato were detectable at the site of injection 12 weeks post-implantation, suggesting the engraftment of mMPC-SMC in the pyloric sphincter (Fig. 6b). Immunohistological examination for TdTomato and aSMA proteins revealed that TdTomato expressing cells were found within the pyloric sphincter circular muscle as well as muscularis mucosa (Fig. 6c). In addition, TdTomato-positive cells that are located within the smooth muscle layer of the pyloric sphincter expressed aSMA demonstrate the smooth muscle phenotype of mMPC-SMC after engraftment (Fig. 6c).
The present study provides to our knowledge the first evidence that skeletal muscle-derived MPC can be differentiated into smooth muscle cells in vitro and thereby express contractile proteins, surface markers, as well as functional voltage-gated ion channels associated with smooth muscle lineage commitment. Furthermore, we report that this differentiation is stable even when MPC-SMC are removed from smooth muscle differentiating conditions. Importantly, we underscore the potential of MPC-SMC for sphincter regeneration by demonstrating the engraftment, survival, and contractile protein expression of MPC-SMC following transplantation into the murine pyloric sphincter in vivo.
To date, different sources of human cells capable of in vitro differentiation towards the smooth muscle lineage have been described, whereby most studies included induced pluripotent stem cells (iPSC) and MSC [18, 19, 35]. Both iPSC and MSC can be isolated without ethical concerns and harbor great differentiation potential; high proliferative capacities are easily accessible as well as clinically suitable for autologous treatment approaches [43, 44]. iPSC especially are promising in their smooth muscle differentiation potential and functionality in vitro , and iPSC-derived smooth muscle progenitor cells demonstrated urethral sphincter regenerative potential in vivo . However, concerns on safety, such as genetic instability and teratoma formation, still dampen their way into the clinics . Adult MSC-derived cell products did not cause major health concerns in the majority of clinical trials . They have been shown effective for anal sphincter muscle regeneration in animal models , although their clinical efficacy remains elusive and the mode of action is yet to be elucidated. Primary smooth muscle cells were successfully used for smooth muscle regeneration in a passive fecal incontinence animal model . However, these cells are hardly accessible for autologous treatment in humans, and moreover, they are heterogeneous in nature and may have limited in proliferative capacity . Therefore, primary smooth muscle cells do not qualify as a promising cell therapeutic candidate for smooth muscle regeneration in humans. In contrast, skeletal muscle-derived cells are highly proliferative , and CD56+ cells have been shown to be safe and effective in clinical trials to treat external anal sphincter-associated (skeletal muscle) fecal incontinence [21, 22, 24]. With this study, we demonstrate that CD56+ skeletal muscle-derived cells (MPC) also possess the potential to differentiate into functional smooth muscle in vitro, being able to engraft into the pyloric sphincter smooth muscle, following intramuscular implantation. Thus, skeletal muscle-derived CD56+ MPC have both skeletal and smooth muscle regenerative potential and therefore constitute a unique and powerful cell source for cell therapy in patients with defects in both skeletal and/or smooth muscle sphincters.
A previous study reported the capacity of CD34+/CD56+ muscle-derived cells having smooth muscle differentiation potential in vitro . CD34 expression was described in muscle-derived stem cells and quiescent satellite cells , but its expression becomes heterogeneous during activation and proliferation . Thus, it became questionable if CD34− muscle-derived cells maintain their smooth muscle differentiation potential. MPC isolated in the present study were found to be CD34−, and thus, our results for the first time demonstrate that CD34−/CD56+ MPC maintain smooth muscle differentiation potential. Our results showed for the first time to our knowledge that treatment of CD34− /CD56+ MPC in smooth muscle differentiation medium containing TGFb1 and heparin induced expression of smooth muscle-associated proteins (aSMA and smoothelin) and maintained expression of the myogenic marker desmin. Convincingly, CD146, a marker associated with the vascular lineage commitment of MSC  and also detected in synthetic human bladder-derived smooth muscle cells (s-hBd-SMC), and CD49a (ITGA1), a marker dramatically increased in smooth muscle containing tissue during development  and detected in contractile human bladder-derived smooth muscle cells, were found in MPC-SMC. This suggests that MPC-SMC adopt surface marker profile of smooth muscle cells. Furthermore, MPC to MPC-SMC differentiation was shown herein to reduce cell proliferation consistent with differentiation and findings of others that CD146+ smooth muscle lineage-committed cells proliferate significantly slower than CD146− cells .
In our study, we demonstrated that MPC-derived MPC-SMC also express functional calcium and potassium channels. Furthermore, a comparison of changes in the pattern of gene expression between MPC and MSC during smooth muscle differentiation revealed highly similar differentiation efficiency. This suggests MPC are at least as good as MSC to generate smooth muscle cells in vitro. Although an upregulated protein expression of aSMA could be detected in MPC-SMC, we detected upregulation of ACTA2 gene expression encoding aSMA only following the smooth muscle cell differentiation of MSC, but not MPC. The higher amount of aSMA protein-positive cells MPC-SMC compared to MPC could result from (i) an increased polymerization of globular actin (G-aSMA) into filamentous actin (F-aSMA), of which only the latter is detectable by aSMA antibodies , or (ii) post-transcriptional regulation of aSMA protein expression during MPC to MPC-SMC differentiation.
Contractility of smooth muscle cells is a prerequisite for their functionality in vivo, and an increase in contractility of in vitro generated smooth muscle cells was already confirmed for adipose- and bone marrow MSC-derived smooth muscle cells [19, 35]. Our results go along with these findings as skeletal muscle-derived MSC found herein increased in contractility upon in vitro smooth muscle differentiation to MSC-SMC. Strikingly, we could demonstrate for the first time increased contractility of MPC following in vitro differentiation to MPC-SMC, comparable to the contractility of MSC-SMC. However, the contractility of SMC was not yet as pronounced as of hBd-SMC, suggesting that MPC-SMC are on their way to become fully mature contractile smooth muscle cells.
Previous studies used muscle-derived cells for the treatment of detrusor muscle dysfunction [27, 54]. Although improvement of bladder function following cryoinjury was reported, injected cells also formed skeletal muscle fibers within the smooth muscle tissue . In this case, improvement of bladder function could be explained by increasing the total amount of tissue and thus compensate for lost tissue. However, this mere replacement of tissue by cells not having the same functionality as lost cells might not be regenerative. In contrast, we provide evidence that murine MPC-SMC generated according to our protocol, survived within the pyloric sphincter of immunodeficient mice, and express aSMA. Importantly, we did not find skeletal myofibers within the smooth muscle tissue of the pyloric sphincter following transplantation, suggesting smooth muscle lineage commitment stability. Moreover, our in vitro data demonstrated that human MPC-SMC exhibit less skeletal myogenic differentiation potential (fusion competence, AChE, and CK activity) than MPC, which might put them in favor as a therapy for smooth muscle regeneration.
The smooth muscle differentiation potential of MPC in vitro as well as the integration capacity of MPC-SMC in the sphincter muscle makes them an auspicious candidate for regenerative therapy in conditions such as passive fecal incontinence. Further studies addressing the safety and efficacy of MPC-SMC in smooth muscle sphincter regeneration will be required. The establishment of faithful small and large animal disease models for sphincter regeneration will be pivotal for gathering new insight into the functional regenerative potentials of MPC-SMC and the establishment of effective smooth muscle regeneration therapies.
Human skeletal muscle-derived myogenic progenitor cells demonstrate smooth muscle differentiation potential in vitro. Smooth muscle differentiation of myogenic progenitor cells was induced by cultivating them in TGFb1 and heparin-containing medium. Resulting smooth muscle cells demonstrate increased expression of smooth muscle marker genes and proteins, as well as functional voltage-gated cation channels and in vitro contractility. These in vitro-generated smooth muscle cells engraft in sphincter smooth muscle tissue following intramuscular implantation in vivo. Taken together, myogenic progenitor cell-derived smooth muscle cells could be a promising medicinal product for the treatment of smooth muscle sphincter-related disorders such as passive fecal incontinence.
Availability of data and materials
All data generated or analyzed during this study are included in this published article and its supplementary information files.
Alpha smooth muscle actin
- Cav :
Voltage-gated calcium channels
Cluster of differentiation
Filamentous alpha smooth muscle actin
Globular alpha smooth muscle actin
Good Manufacturing Practice
Contractile human bladder-derived smooth muscle cells
Human bladder-derived smooth muscle cells
Induced pluripotent stem cells
- Kv :
Voltage-gated potassium channels
Magnetic-activated cell sorting
Murine myogenic progenitor cells
Myogenic progenitor cells
Myogenic progenitor cell-derived smooth muscle cells
Multipotent mesenchymal stromal cells
Multipotent mesenchymal stromal cell-derived smooth muscle cell
Standard error of the mean
Synthetic human bladder-derived smooth muscle cells
Smooth muscle cells
Smooth muscle myosin heavy chain
Transforming growth factor beta
Al-Ali S, Blyth P, Beatty S, Duang A, Parry B, Bissett IP. Correlation between gross anatomical topography, sectional sheet plastination, microscopic anatomy and endoanal sonography of the anal sphincter complex in human males. J Anat. 2009;215(2):212–20.
Ramkumar D, Schulze KS. The pylorus. Neurogastroenterol Motil Off J Eur Gastrointest Motil Soc. 2005;17(Suppl 1):22–30.
Rao SSC. Pathophysiology of adult fecal incontinence. Gastroenterology. 2004;126(1 Suppl 1):S14–22.
Abrahamsson H. Treatment options for patients with severe gastroparesis. Gut. 2007;56(6):877–83.
Meyer I, Richter HE. Impact of fecal incontinence and its treatment on quality of life in women. Womens Health Lond Engl. 2015;11(2):225–38.
Goode PS, Burgio KL, Halli AD, Jones RW, Richter HE, Redden DT, et al. Prevalence and correlates of fecal incontinence in community-dwelling older adults. J Am Geriatr Soc. 2005;53(4):629–35.
Quander CR, Morris MC, Melson J, Bienias JL, Evans DA. Prevalence of and factors associated with fecal incontinence in a large community study of older individuals. Am J Gastroenterol. 2005;100(4):905–9.
Mimura T, Kaminishi M, Kamm MA. Diagnostic evaluation of patients with faecal incontinence at a specialist institution. Dig Surg. 2004;21(3):235–41.
Vaizey CJ, Kamm MA, Bartram CI. Primary degeneration of the internal anal sphincter as a cause of passive faecal incontinence. Lancet Lond Engl. 1997;349(9052):612–5.
Wang JY, Abbas MA. Current management of fecal incontinence. Perm J. 2013;17(3):65–73.
van Eys GJ, Niessen PM, Rensen SS. Smoothelin in vascular smooth muscle cells. Trends Cardiovasc Med. 2007;17(1):26–30.
Capetanaki Y, Milner DJ, Weitzer G. Desmin in muscle formation and maintenance. Cell Struct Funct. 1997;22(1):103–16.
Wang J, Zohar R, McCulloch CA. Multiple roles of alpha-smooth muscle actin in mechanotransduction. Exp Cell Res. 2006;312(3):205–14.
Sanders KM. Regulation of smooth muscle excitation and contraction. Neurogastroenterol Motil Off J Eur Gastrointest Motil Soc. 2008;20(Suppl 1):39–53.
Guo X, Chen S-Y. Transforming growth factor-beta and smooth muscle differentiation. World J Biol Chem. 2012;3(3):41–52.
Wang N, Ren G-D, Zhou Z, Xu Y, Qin T, Yu R-F, et al. Cooperation of myocardin and smad2 in inducing differentiation of mesenchymal stem cells into smooth muscle cells. IUBMB Life. 2012;64(4):331–9.
Jeon ES, Park WS, Lee MJ, Kim YM, Han J, Kim JH. A rho kinase/myocardin-related transcription factor-A–dependent mechanism underlies the sphingosylphosphorylcholine-induced differentiation of mesenchymal stem cells into contractile smooth muscle cells. Circ Res. 2008;103(6):635–42.
Bajpai VK, Mistriotis P, Loh Y-H, Daley GQ, Andreadis ST. Functional vascular smooth muscle cells derived from human induced pluripotent stem cells via mesenchymal stem cell intermediates. Cardiovasc Res. 2012;96(3):391–400.
Park WS, Heo SC, Jeon ES, Hong DH, Son YK, Ko J-H, et al. Functional expression of smooth muscle-specific ion channels in TGF-beta(1)-treated human adipose-derived mesenchymal stem cells. Am J Physiol Cell Physiol. 2013;305(4):C377–91.
Yin H, Price F, Rudnicki MA. Satellite cells and the muscle stem cell niche. Physiol Rev. 2013;93(1):23–67.
Frudinger A, Kolle D, Schwaiger W, Pfeifer J, Paede J, Halligan S. Muscle-derived cell injection to treat anal incontinence due to obstetric trauma. Gut. 2009;59(01):55–61.
Frudinger A, Pfeifer J, Paede J, Kolovetsiou-Kreiner V, Marksteiner R, Halligan S. Autologous skeletal-muscle-derived cell injection for anal incontinence due to obstetric trauma. Color Dis. 2015;17(9):794–801.
Frudinger A, Kölle D, Schwaiger W, Pfeifer J, Paede J, Halligan S. Muscle-derived cell injection to treat anal incontinence due to obstetric trauma: pilot study with 1 year follow-up. Gut. 2010;59(1):55–61.
Frudinger A, Marksteiner R, Pfeifer J, Margreiter E, Paede J, Thurner M. Skeletal muscle-derived cell implantation for the treatment of sphincter-related faecal incontinence. Stem Cell Res Ther. 2018;9(1):233.
Boyer O, Bridoux V, Giverne C, Bisson A, Koning E, Leroi A-M, et al. Autologous myoblasts for the treatment of fecal incontinence: results of a phase 2 randomized placebo-controlled study (MIAS). Ann Surg. 2018;267(3):443–50.
Romaniszyn M, Rozwadowska N, Malcher A, Kolanowski T, Walega P, Kurpisz M. Implantation of autologous muscle-derived stem cells in treatment of fecal incontinence: results of an experimental pilot study. Tech Coloproctology. 2015;19(11):685–96.
Huard J, Yokoyama T, Pruchnic R, Qu Z, Li Y, Lee JY, et al. Muscle-derived cell-mediated ex vivo gene therapy for urological dysfunction. Gene Ther. 2002;9(23):1617–26.
Lu S-H, Lin ATL, Chen K-K, Chiang HS, Chang LS. Characterization of smooth muscle differentiation of purified human skeletal muscle-derived cells. J Cell Mol Med. 2011;15(3):587–92.
Thurner M, Asim F, Garczarczyk-Asim D, Janke K, Deutsch M, Margreiter E, et al. Development of an in vitro potency assay for human skeletal muscle derived cells. PLoS One. 2018;13(3):e0194561.
THURNER M, MARGREITER E, Schwaiger W, ASIM FM, Marksteiner R. Methods for obtaining muscle derived cells [Internet]. WO2019115790A1, 2019 [cited 2020 Mar 23]. Available from: https://patents.google.com/patent/WO2019115790A1/en?q=marco&inventor=thurner&oq=thurner+marco.
Belles-Isles M, Roy R, Dansereau G, Goulet M, Roy B, Bouchard JP, et al. Rapid selection of donor myoblast clones for muscular dystrophy therapy using cell surface expression of NCAM. Eur J Histochem EJH. 1993;37(4):375–80.
Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–7.
Niessen P, Rensen S, van Deursen J, Man JD, Laet AD, Vanderwinden J-M, et al. Smoothelin-A is essential for functional intestinal smooth muscle contractility in mice. Gastroenterology. 2005;129(5):1592–601.
Paulin D, Li Z. Desmin: a major intermediate filament protein essential for the structural integrity and function of muscle. Exp Cell Res. 2004;301(1):1–7.
Espagnolle N, Guilloton F, Deschaseaux F, Gadelorge M, Sensébé L, Bourin P. CD146 expression on mesenchymal stem cells is associated with their vascular smooth muscle commitment. J Cell Mol Med. 2014;18(1):104–14.
Belkin VM, Belkin AM, Koteliansky VE. Human smooth muscle VLA-1 integrin: purification, substrate specificity, localization in aorta, and expression during development. J Cell Biol. 1990;111(5 Pt 1):2159–70.
Miano JM. Vascular smooth muscle cell differentiation-2010. J Biomed Res. 2010;24(3):169–80.
Xie C-Q, Ritchie RP, Huang H, Zhang J, Chen YE. Smooth muscle cell differentiation in vitro: models and underlying molecular mechanisms. Arterioscler Thromb Vasc Biol. 2011;31(7):1485–94.
KEGG PATHWAY: vascular smooth muscle contraction - Homo sapiens (human) [Internet]. [cited 2017 Dec 20]. Available from: http://www.genome.jp/kegg-bin/show_pathway?map=hsa04270&show_description=show.
Wang R, Li Q, Tang DD. Role of vimentin in smooth muscle force development. Am J Physiol - Cell Physiol. 2006;291(3):C483–9.
Cassar-Malek I, Barjot C, Bacou F. Expression of acetylcholinesterase molecular forms during in vitro differentiation of rabbit embryonic muscle cells. C R Acad Sci III. 1993;316(4):346–51.
Zalin R. Creatine kinase activity in cultures of differentiating myoblasts. Biochem J. 1972;130(2):79P.
Jung Y, Bauer G, Nolta JA. Concise review: induced pluripotent stem cell-derived mesenchymal stem cells: progress toward safe clinical products. Stem Cells Dayt Ohio. 2012;30(1):42–7.
Pittenger MF. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143–7.
Li Y, Wen Y, Wang Z, Wei Y, Wani P, Green M, et al. Smooth muscle progenitor cells derived from human pluripotent stem cells induce histologic changes in injured urethral sphincter. Stem Cells Transl Med. 2016;5(12):1719–29.
Wang Y, Han Z, Song Y, Han ZC. Safety of mesenchymal stem cells for clinical application. Stem Cells Int [Internet]. 2012 [cited 2018 Jan 11];2012. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3363282/.
Salcedo L, Penn M, Damaser M, Balog B, Zutshi M. Functional outcome after anal sphincter injury and treatment with mesenchymal stem cells. Stem Cells Transl Med. 2014;3(6):760–7.
Bohl JL, Zakhem E, Bitar KN. Successful treatment of passive fecal incontinence in an animal model using engineered biosphincters: a 3-month follow-up study. Stem Cells Transl Med. 2017;6(9):1795–802.
Sandison M, McCarron J. Heterogeneity in the proliferative capacity of smooth muscle cells (SMCs). FASEB J. 2015;29(1 Supplement):418.8.
Wernig A, Schäfer R, Knauf U, Mundegar RR, Zweyer M, Högemeier O, et al. On the regenerative capacity of human skeletal muscle. Artif Organs. 2005;29(3):192–8.
Qu-Petersen Z, Deasy B, Jankowski R, Ikezawa M, Cummins J, Pruchnic R, et al. Identification of a novel population of muscle stem cells in mice: potential for muscle regeneration. J Cell Biol. 2002;157(5):851–64.
Beauchamp JR, Heslop L, Yu DSW, Tajbakhsh S, Kelly RG, Wernig A, et al. Expression of Cd34 and Myf5 defines the majority of quiescent adult skeletal muscle satellite cells. J Cell Biol. 2000;151(6):1221–34.
Andersen P, Small JV, Andersen HK, Sobieszek A. Reactivity of smooth-muscle antibodies with F- and G-actin. Immunology. 1979;37(3):705–9.
Chancellor MB, Yokoyama T, Tirney S, Mattes CE, Ozawa H, Yoshimura N, et al. Preliminary results of myoblast injection into the urethra and bladder wall: a possible method for the treatment of stress urinary incontinence and impaired detrusor contractility. Neurourol Urodyn. 2000;19(3):279–87.
We would like to thank Eva Margreiter for the GMP-compliant production of skeletal muscle-derived cells and the provision of residual material from clinical trials for research use. Further, we would like to thank Raffaela Torggler for proofreading and critically reviewing the manuscript. Additionally, we would like to thank Dominic Pirchner for the excellent assistance in fluorescent cell counting and fusion index calculation.
Innovacell Biotechnologie AG funded this work. Additional funding was received from the Austrian Science Fund (FWF) grant P27729. The funding bodies did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Ethics approval and consent to participate
Muscle samples of human origin were taken as a part of clinical trials (EudraCT numbers: 2010-021463-32 and 2010-021871-10). Residual material of patients agreeing to further usage of their cells was used for research purposes following undersigned informed consent. The national authorities in Austria (BASG), Germany (PEI), Czech Republic (SUKL), the UK (MHRA), and Bulgaria (Bulgarian Drug Agency) (for 2010-021463-32 and 2010-021871-10) as well as Sweden (MPA), Switzerland (Swiss Medic), and Slovenia (JAZMP) (for 2010-021463-32) and Italy (Italian Medicines Agency) (for 2010-021871-10) authorized the clinical trials. In each country, at least one (central) ethics commission was addressed and gave a positive opinion on the trial protocols and informed consents. For clinical trial 2010-021463-32, the following ethics commissions expressed their positive opinion: The “Ethikkomission der Medizinischen Universität Graz (23-099 ex 10/11)” in Austria, the “Medizinische Ethik-Komission II der Medizinischen Fakultät Mannheim” in Germany, the “Regional Ethics Committee Stockholm” in Sweden, the “Central Ethics Committee of the Ministry of Health of the Czech Republic” in the Czech Republic, the “National Research Ethics Service NRES Committee London – Chelsea” in GB, the “Republic of Slovenia National Medical Ethics Committee (NMEC)” in Slovenia, the “Комисията по етика за многоцентрови изпитвания” in Bulgaria, the “Comité de Protection des Personnes – CPP Sud Méditerranée IV” in France, and the “Kantonale Ethikkomission Zürich” in Switzerland. For clinical trial 2010-021871-10, the following ethics commissions expressed their positive opinion: the “Ethik-Kommission der Medizinischen Universität Wien” in Austria; the “Medizinische Ethik der Universität Duisburg – Essen” in Germany; the “Ethics commission of Hradec Kralove” in the Czech Republic; the “Комисията по етика за многоцентрови изпитвания” in Bulgaria; the “NHS, Health Research Authority NRES Committee Yorkshire & The Humber – Leeds” in GB; and the “Comitato Etico Azienda Ospedaliero Universitaria Ospedali Riuniti” in Italy.
Animal experiments within this study were designed and conducted according to the Austrian National Law TVG/2012 (“Tierversuchsgesetz”) and the European Directive 2010/63/EU. Animal experiment proposals were granted by the Government of Salzburg, Austria (project number: 20901-TVG/96/7-2014), and the Federal Ministry of Science Research and Economy (project number: BMWFW-66.019/0039-WF/V/3b/2016). The animal ethics commission of the Paracelsus Medical University, Salzburg, approved the projects.
Consent for publication
No individual person’s data presented within the study.
Innovacell Biotechnologie AG, a clinical-stage biotech company, developing cell-based therapies for commercialization, funded this research within this study. Innovacell Biotechnologie AG employed Marco Thurner, Martin Deutsch, Katrin Janke, Martin Deutsch, and Rainer Marksteiner and provided support in the form of salaries for these authors. The specific roles of authors employed by Innovacell Biotechnologie AG are articulated in the “Authors’ contributions” section.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Additional file 1: S1 Fig. Surface marker expression in synthetic and contractile hBd-SMC compared to MPC and MPC-SMC. Immunocytochemistry against CD146 or CD49a combined each with hematoxylin staining on MPC and SMCs cultivated in either growth medium (MPC and s-hBd-SMC) or smooth muscle differentiation medium (MPC-SMC and hBd-SMC) for 6 days. Representative images of MPC/MPC-SMC from at least two individual muscle biopsies and of two individual experiments (hBd-SMC and s-hBd-SMC). Scale bar = 100 μm.
Additional file 2: S2 Fig. Contractile protein expression in bladder smooth muscle cells compared to MSC-SMC and MPC-SMC. Human skeletal muscle-derived MPC-SMC and MSC-SMC were compared to bladder smooth muscle-derive hBd-SMC by immunostaining for aSMA (green), SM-MHC (green), desmin (red) and vimentin (green), each combined by nuclear staining with Hoechst dye (blue). Representative images from at least three individual experiments are shown. Scale bars = 100 μm.
Additional file 3: S3 Fig. Contractility measurements in collagen gel lattices. Contractility of MPC, MSC, MPC-SMC and MSC-SMC as well as hBd-SMC was quantified by collagen gel lattice contraction. (A) Percent gel contraction from original size within 48 h of cells is shown in bar graphs. Data presented as mean ± SEM of cell preparations from each at least three individual human muscle biopsies (MSC, MPC) or three individual experiments (hBd-SMC). (B) Representative stereomicroscopic images of the collagen gels with embedded MSC, MSC and SMC each derived thereof as well as hBd-SMC in wells of a 24-well plate 48 h after gel formation.
Additional file 4: S4 Fig. Characterization of murine MPC and MPC-SMC. (A) AChE and (B) CK activity was measured by enzyme kinetics and is represented by OD412nm and OD340nm at specific time points (AChE: 60 min, CK: 10 min). Enzyme activities were compared between skeletal muscle-derived mMPC and non-myogenic cells after 6 days in skeletal muscle differentiation medium. (C) Desmin expression of mMPC visualized by immunofluorescence staining. (D) Formation of multinucleated myotubes by mMPC during differentiation in skeletal muscle differentiation medium for six days in vitro was observed. TdTomato and nuclei were stained on histological cross sections of tibialis anterior muscles of (E) control untreated mice and (F) SHO mice 70 days after intramuscular injection with TdTomato mMPC and fluorescent beads. Scale bar = 100 μm.
About this article
Cite this article
Thurner, M., Deutsch, M., Janke, K. et al. Generation of myogenic progenitor cell-derived smooth muscle cells for sphincter regeneration. Stem Cell Res Ther 11, 233 (2020). https://doi.org/10.1186/s13287-020-01749-w
- Skeletal muscle-derived cells
- Smooth muscle
- Myogenic progenitor cells
- Satellite cells
- Smooth muscle regeneration
- Cell therapy
- Regenerative medicine
- Sphincter regeneration
- Fecal incontinence
- Tissue engineering